This site is intended for health professionals only!

B-MS drops co-operative HIV venture


Sweden’s Medivir has been told that partner Bristol-Myers Squibb has terminated development of the firms’ preclinical HIV compound MIV-170.

The decision was taken “because the compound did not meet the profile desired” by the New York-based drugs major. The Swedish firm noted that MIV-170 belongs to a group

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: